EVE is a deep generative model combining evolutionary and human population data to estimate variant deleteriousness on a proteome-wide scale.

The U.S. is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing, and commercial sites.

The U.S. Pharmacopeia has created new standards to support the emerging field of advanced cell and gene therapies.

Precipitation-based purification method could replace current Protein A–reliant methods, significantly reducing manufacturing costs of mAbs.

Sustainable bioprocessing boosts cyanobacterial pigment production for advanced biomedical, imaging, and commercial applications.

Multiple microbial communities populate cleanrooms, regardless of grade, and aren’t detected by standard monitoring methods.

Scripps Research uses advanced AI computing to speed HIV vaccine development by rapidly analyzing clinical data.

ToxPredictor accurately predicts drug induced liver injury (DILI) to offer a valuable “go/no-go” tool in clinical decision making.

This latest corporate clash has Alkermes working to beat back a challenge from H. Lundbeck for sleep disorder drug developer Avadel Pharmaceuticals.

Findings represent a detailed resource for future research that could lead to the development of new biomarkers and targeted therapeutics for T1D.

The Virtual Cell Pharmacology Initiative (VCPI) is an open source platform designed to build a standardized framework for virtual cell models.

Novartis’ $23 billion investment in U.S.-based infrastructure over the next five years is designed to increase manufacturing capacity.